Panicking and abandoning the protocol is the wrong move
Analyst Opinion Sabyasachi Ghosh, Principal Consultant for Healthcare at FMI, suggests, The GLP-1 receptor agonist market is expected to shift toward companies able to combine clinical evidence with reliable supply execution
The varying regulatory standards across different countries can complicate global marketing strategies, as companies must navigate different approval processes and compliance requirements, making market entry challenging
While adenosine triphosphate (ATP) signaling was enhanced, capsaicin sensitivity was unaffected by the acute application of exendin-4 in cultured DRG neurons, suggesting GLP-1R role in modulating gut motility rather than pain signaling
[13] The FDA also considered data from one separate trial (NCT01720446 [76] ), which was sponsored by Novo Nordisk, of 3297 participants with type 2 diabetes who were at high risk for cardiovascular events